REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Tuesday. The biotechnology company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.34, Bloomberg Earnings reports. REGENXBIO had a negative net margin of 1,595.18% and a negative return on equity of 39.52%.

REGENXBIO (NASDAQ:RGNX) traded up 0.54% during mid-day trading on Tuesday, reaching $18.70. 106,438 shares of the company were exchanged. The company’s market capitalization is $576.35 million. REGENXBIO has a one year low of $8.75 and a one year high of $24.55. The stock has a 50-day moving average price of $19.69 and a 200 day moving average price of $19.34.

In other news, insider Kenneth T. Mills sold 6,500 shares of the company’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $19.68, for a total transaction of $127,920.00. Following the completion of the sale, the insider now owns 119,396 shares of the company’s stock, valued at approximately $2,349,713.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Vittal Vasista sold 3,100 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $18.75, for a total transaction of $58,125.00. Following the sale, the chief financial officer now directly owns 107,512 shares of the company’s stock, valued at approximately $2,015,850. The disclosure for this sale can be found here. Insiders have sold a total of 19,200 shares of company stock valued at $368,746 in the last ninety days. Insiders own 17.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “REGENXBIO Inc. (RGNX) Posts Quarterly Earnings Results, Beats Expectations By $0.34 EPS” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/08/regenxbio-inc-rgnx-posts-quarterly-earnings-results-beats-expectations-by-0-34-eps.html.

RGNX has been the subject of several analyst reports. Zacks Investment Research upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Saturday, April 15th. Chardan Capital increased their target price on shares of REGENXBIO from $35.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, April 11th.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Earnings History for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.